Adaptive Biotechnologies (ADPT) Operating Leases (2020 - 2026)

Adaptive Biotechnologies has disclosed Operating Leases across 7 years of filings, most recently posting $66.8 million for Q2 2026.

• In Q2 2026, Operating Leases fell 10.23% year-over-year to $66.8 million; the TTM figure through Jun 2026 stood at $66.8 million (down 10.23% YoY), while the FY2025 annual figure was $70.2 million, down 11.27% from the prior year.
• Operating Leases came in at $66.8 million for Q2 2026 at Adaptive Biotechnologies, down from $69.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $105.0 million in Q1 2022 to a low of $66.8 million in Q2 2026.
• Average Operating Leases over 5 years is $85.6 million, with a median of $85.6 million recorded in 2024.
• Year-over-year, Operating Leases advanced 10.21% in 2022 and fell 12.04% in 2025.
• Over 5 years, Operating Leases stood at $98.8 million in 2022, then decreased by 9.5% to $89.4 million in 2023, then declined by 11.46% to $79.1 million in 2024, then declined by 11.27% to $70.2 million in 2025, then declined by 4.88% to $66.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $66.8 million in Q2 2026, $69.1 million in Q1 2026, and $70.2 million in Q4 2025.